ESMO: Roche's Alecensa staves off lung cancer recurrence en route to postsurgery expansion
Fierce Pharma
OCTOBER 20, 2023
Moving drugs into early-stage cancers is in vogue these days. Moving drugs into early-stage cancers is in vogue these days. Roche has just posted a trial win for its targeted lung cancer therapy Alecensa that should enable earlier use, while eliciting a sense of déjà vu from a study of AstraZeneca’s Tagrisso.
161 
Let's personalize your content